J Corral1,2, D Parés3,4,5, F García-Cuyás1,2, B Revollo2,6, S Videla2,7, A Chamorro2,6, M Piñol1,2, B Clotet2,8,9, G Sirera2,6. 1. Colorectal Surgery Unit, Department of General Surgery, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain. 2. Lluita Contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. 3. Colorectal Surgery Unit, Department of General Surgery, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain. dapares@gmail.com. 4. Lluita Contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. dapares@gmail.com. 5. School of Medicine, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain. dapares@gmail.com. 6. HIV Clinical Unit, Department of Medicine, University Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain. 7. Department of Clinical Pharmacology, University Hospital Bellvitge/IDIBELL/Barcelona University, Hospitalet de Llobregat, Barcelona, Catalonia, Spain. 8. School of Medicine, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain. 9. Retrovirology Laboratory IrsiCaixa Foundation, Badalona, Catalonia, Spain.
Abstract
BACKGROUND: Anal intraepithelial neoplasia (AIN) (or low/high grade squamous intraepithelial neoplasia (L/HSIL)) is the precursor of anal of early invasive anal cancer. Different treatment options for local ablation of localized lesions have been reported. The aim of this study was to analyze the clinical efficacy and safety of infrared coagulation for the treatment of anal dysplasia. METHODS: A search of the literature was performed in 2019 using PubMed and Cochrane to identify all eligible trials published reporting data on the treatment of anal dysplasia with infrared coagulation. The percentage of squamous cell carcinoma of the the anus that developed in the follow-up and results on major complications after treatment were the primary outcomes. RESULTS: Twenty-four articles were identified from which 6 were selected with a total of 360 patients included, with a median age of 41.8 years. Three studies were prospective and 3 retrospective, only one was a randomized trial. All articles included males, 4 articles included HIV-positive women and only one article included non HIV infected males. No patient developed major complications after infrared coagulation therapy. Pain was the most common symptom found after the procedure in the different series and mild bleeding that did not require transfusion was the most common complication occurring in 4 to 78% of patients. Median follow-up was between 4.7 and 69 months. No patient developed squamous cell carcinoma after infrared treatment. Recurrent HSIL varied from 10 to 38%. Two studies reported results from follow-up of untreated patients showing that between 72 and 93% of them had persistent HSIL at last follow-up and 4.8% developed squamous cell carcinoma. CONCLUSIONS: Infrared coagulation is a safe and effective method for ablation of high-grade anal dysplasia that could help prevent anal cancer. Continued surveillance is recommended due to the risk of recurrence.
BACKGROUND:Anal intraepithelial neoplasia (AIN) (or low/high grade squamous intraepithelial neoplasia (L/HSIL)) is the precursor of anal of early invasive anal cancer. Different treatment options for local ablation of localized lesions have been reported. The aim of this study was to analyze the clinical efficacy and safety of infrared coagulation for the treatment of anal dysplasia. METHODS: A search of the literature was performed in 2019 using PubMed and Cochrane to identify all eligible trials published reporting data on the treatment of anal dysplasia with infrared coagulation. The percentage of squamous cell carcinoma of the the anus that developed in the follow-up and results on major complications after treatment were the primary outcomes. RESULTS: Twenty-four articles were identified from which 6 were selected with a total of 360 patients included, with a median age of 41.8 years. Three studies were prospective and 3 retrospective, only one was a randomized trial. All articles included males, 4 articles included HIV-positive women and only one article included non HIV infected males. No patient developed major complications after infrared coagulation therapy. Pain was the most common symptom found after the procedure in the different series and mild bleeding that did not require transfusion was the most common complication occurring in 4 to 78% of patients. Median follow-up was between 4.7 and 69 months. No patient developed squamous cell carcinoma after infrared treatment. Recurrent HSIL varied from 10 to 38%. Two studies reported results from follow-up of untreated patients showing that between 72 and 93% of them had persistent HSIL at last follow-up and 4.8% developed squamous cell carcinoma. CONCLUSIONS: Infrared coagulation is a safe and effective method for ablation of high-grade anal dysplasia that could help prevent anal cancer. Continued surveillance is recommended due to the risk of recurrence.
Authors: Khaled A Hamdan; Iain S Tait; Valerie Nadeau; Miles Padgett; Frank Carey; Robert J Steele Journal: Dis Colon Rectum Date: 2003-11 Impact factor: 4.585
Authors: Elizabeth A Stier; Stephen E Goldstone; J Michael Berry; Lori A Panther; Naomi Jay; Susan E Krown; Jeannette Lee; Joel M Palefsky Journal: J Acquir Immune Defic Syndr Date: 2008-01-01 Impact factor: 3.731
Authors: Christophe Piketty; Teresa M Darragh; Maria Da Costa; Patrick Bruneval; Isabelle Heard; Michel D Kazatchkine; Joel M Palefsky Journal: Ann Intern Med Date: 2003-03-18 Impact factor: 25.391
Authors: Yoojin Choi; Mona Loutfy; Robert S Remis; Juan Liu; Anuradha Rebbapragada; Sanja Huibner; Jason Brunetta; Graham Smith; Tatjana Reko; Roberta Halpenny; Rupert Kaul; Troy Grennan Journal: Sci Rep Date: 2021-02-26 Impact factor: 4.379